Ionic Contraviral Therapy- ICVT

Recurrent Respiratory Papillomatosis (RRP)

Background
RRP is a rare, yet life threatening disease that typically infects the respiratory tract of children. It occurs when the lining of the lung or upper airways become infected predominately by the same types of human papillomavirus (HPV) that cause genital warts – types 6 and 11.

The papillomas in RRP are found mainly in the larynx and on the vocal chords, but they can spread into the trachea and lungs. Papillomas can be deadly in paediatric RRP due to the small size of the upper airway in children. Death can occur from airway obstruction, cancerous transformation, the overwhelming spread of the disease, or complications of surgical treatments. Currently, the only treatment available for RRP is surgery. There are no approved drugs or immunotherapies. Paediatric patients have on average 4-5 surgeries per year and some children have hundreds of surgeries during their lifetimes.

As the disease is so rare (approximately 20,000 cases in the USA) it qualifies for “Orphan Status”- a special category of disease that gives drug developers certain advantages to enable a speedy route to market. Henderson Morley are developing a formulation that is targeted at RRP, and studies are planned to examine its use in man.

Next: Animal Health